Shingles Vaccine Shows Promising Link to Reduced Dementia Risk in Landmark Welsh Study

An unusual vaccination rule in Wales has given scientists some of the clearest evidence so far that a vaccine might help protect against dementia. In a new study led by Stanford Medicine, researchers examined health records from older adults in Wales and found that people who received the shingles vaccine were 20% less likely to be diagnosed with dementia over the following seven years than those who did not receive the shot. This significant finding, published April 2 in the prestigious journal Nature, adds substantial weight to a growing scientific hypothesis: that certain viruses affecting the nervous system may elevate the risk of developing dementia. If these initial findings continue to be corroborated by future work, they suggest that a practical and widely available method to help prevent or even slow the progression of dementia could already exist. Further reinforcing this potential, a second analysis from the same research team, published December 2 in Cell, pointed to another crucial benefit: the vaccine might also aid individuals already living with dementia by slowing the rate at which their condition worsens.

The Global Burden of Dementia and the Emerging Viral Hypothesis

Dementia, a broad term for a decline in mental ability severe enough to interfere with daily life, currently affects more than 55 million people worldwide, with approximately 10 million new cases diagnosed every year. This makes it one of the most pressing global health challenges of our time, imposing immense emotional, social, and economic burdens on individuals, families, and healthcare systems. For decades, much of the research into dementia, particularly Alzheimer’s disease—the most common form—has focused on the accumulation of abnormal proteins in the brain, such as amyloid plaques and tau tangles. Despite extensive efforts and significant investment, these research avenues have not yet yielded universally successful ways to prevent or halt the disease’s progression. This lack of breakthroughs has prompted some scientists to broaden their investigative scope, turning their attention to other potential drivers, including chronic infections by specific viruses that may inflict cumulative damage on the brain over time. This paradigm shift has given rise to the "viral hypothesis" of dementia, suggesting that dormant viruses could play a role in neurodegeneration.

Varicella-Zoster Virus: From Chickenpox to Shingles to Potential Dementia Link

The shingles vaccine targets the varicella-zoster virus (VZV), the same pathogen responsible for chickenpox. Typically contracted in childhood, chickenpox is an acute, highly contagious illness characterized by an itchy, blistering rash. While the visible symptoms of chickenpox eventually subside, the VZV does not entirely leave the body. Instead, it retreats into a dormant, or latent, state within the sensory nerve cells of the spinal cord and brain. For most of a person’s life, the virus remains inactive, posing no immediate threat. However, in later years, particularly as the immune system naturally weakens with age, or in individuals with compromised immune systems due to illness or medication, this dormant virus can reactivate. When VZV reactivates, it travels along the nerve pathways to the skin, causing shingles (herpes zoster)—a painful, blistering rash that typically appears in a band or strip on one side of the body. The pain associated with shingles can be severe and long-lasting, a condition known as postherpetic neuralgia. The hypothesis linking VZV to dementia suggests that repeated reactivations of the virus, even subclinical ones that don’t manifest as a full shingles rash, could trigger chronic inflammation or direct damage to brain tissue, contributing to neurodegenerative processes over decades.

Overcoming Methodological Hurdles: The Welsh "Natural Experiment"

Earlier observational studies, which utilized health records to explore a potential link between shingles vaccination and reduced dementia risk, had offered tantalizing hints. However, these studies were plagued by a significant methodological limitation: self-selection bias. Individuals who actively choose to get vaccinated often exhibit a broader pattern of health-conscious behaviors that are difficult to quantify. They might adhere to healthier diets, engage in more regular physical activity, or interact with healthcare providers more frequently. These lifestyle factors are independently known to influence dementia risk, yet they are rarely comprehensively recorded in standard medical databases. This made it challenging to definitively attribute any observed protective effect solely to the vaccine.

"All these associational studies suffer from the basic problem that people who go get vaccinated have different health behaviors than those who don’t," explained Pascal Geldsetzer, MD, PhD, assistant professor of medicine at Stanford and senior author of the new study. "In general, they’re seen as not being solid enough evidence to make any recommendations on."

Approximately two years ago, Dr. Geldsetzer and his team recognized a unique opportunity presented by the specific rollout strategy of Wales’s national shingles vaccination program. This setup functioned as what researchers term a "natural experiment," ingeniously designed to circumvent much of the bias inherent in prior observational studies. The program, which commenced on September 1, 2013, utilized a version of the shingles vaccine containing a live-attenuated, or weakened, form of the virus (Zostavax, which was the primary vaccine available globally at the time).

Under this policy, eligibility for the vaccine was strictly determined by age on a specific cut-off date. Anyone who was 79 years old on September 1, 2013, became eligible to receive the vaccine during the subsequent year. This eligibility rolled over annually; for example, those turning 78 would become eligible the following year for a one-year window, and so on. Crucially, individuals who were 80 years old or older on September 1, 2013, were deemed ineligible and would never become eligible for the vaccine under this particular program phase.

This precise age-based cut-off created a nearly perfect comparative scenario. The difference between being just under or just over the age threshold had a profound, yet arbitrary, impact on vaccine access. This allowed the researchers to compare two groups of individuals who were virtually identical in all measurable respects except for their eligibility for the vaccine: those who turned 80 shortly before September 1, 2013, and those who turned 80 shortly after. "We know that if you take a thousand people at random born in one week and a thousand people at random, born a week later, there shouldn’t be anything different about them on average," Geldsetzer stated. "They are similar to each other apart from this tiny difference in age." The detailed and comprehensive health records available in Wales further enhanced the robustness of this "natural experiment," making the circumstances as close as possible to a randomized controlled trial (RCT) without actually conducting one.

Detailed Findings: Protection Against Onset and Progression

To leverage this unique methodological advantage, Dr. Geldsetzer’s team analyzed the anonymized health records of more than 280,000 older adults in Wales, ranging in age from 71 to 88 years at the program’s inception, all of whom were dementia-free at that time. The core of their analysis concentrated on individuals whose birthdays positioned them just on either side of the eligibility line, specifically comparing those who turned 80 in the week before September 1, 2013, with those who turned 80 in the week after.

The researchers reasoned that the inherent desire or inclination to receive the shingles shot would be approximately the same in both groups. The critical differentiator was the policy itself: only the slightly younger cohort, those not yet 80 on the cut-off date, were legally permitted to receive the vaccine. "What makes the study so powerful is that it’s essentially like a randomized trial with a control group – those a little bit too old to be eligible for the vaccine – and an intervention group – those just young enough to be eligible," Geldsetzer emphasized.

The team then meticulously tracked the health outcomes for these cohorts over the subsequent seven years. By combining information on eligibility with actual vaccination rates, they could estimate the real-world effect of receiving the shot. Approximately half of the eligible individuals chose to be vaccinated, while, as expected, almost none of the ineligible group received it.

The immediate and expected outcome was a reduction in shingles incidence. Among those who were vaccinated, the rate of shingles over the seven-year follow-up period decreased by approximately 37%, a figure consistent with established clinical trial data for the live-attenuated vaccine, whose effectiveness is known to wane over time.

However, the more profound discovery emerged when examining dementia diagnoses. By 2020, when the individuals under study were approximately 86 and 87 years old, a significant proportion—one in eight—had developed dementia. Strikingly, among those who received the shingles shot, the likelihood of a dementia diagnosis was 20% lower compared with their unvaccinated counterparts. "It was a really striking finding," Geldsetzer recalled. "This huge protective signal was there, any which way you looked at the data."

Robustness of Findings: Ruling Out Other Explanations

To ensure the observed link was genuinely attributable to the vaccine and not other confounding factors, the researchers conducted extensive analyses. They systematically searched for any other differences between the eligible and ineligible groups that might explain the disparity in dementia rates. Their investigations revealed that the two groups were remarkably similar across all measurable characteristics. Education levels were consistent between eligible and ineligible individuals. Crucially, those eligible for the shingles vaccine were not found to be more likely to receive other vaccines or preventive therapies, nor were they less likely to suffer from common chronic illnesses such such as diabetes, heart disease, or cancer. The only clear and statistically significant difference between the groups was the notably lower number of dementia diagnoses in those who had access to and received the shingles shot.

"Because of the unique way in which the vaccine was rolled out, bias in the analysis is much less likely than would usually be the case," Geldsetzer asserted. Even with this inherent methodological strength, the team subjected the data to a battery of alternative tests. They examined different age windows for eligibility, focused solely on deaths where dementia was listed as a primary cause, and applied various statistical models. Regardless of how the information was sliced and analyzed, the robust relationship between shingles vaccination and a reduced risk of dementia consistently remained. "The signal in our data was so strong, so clear and so persistent," he added.

Beyond Prevention: Slowing Progression and Gender Disparities

The researchers extended their inquiry beyond just preventing dementia onset. They asked whether the apparent benefits of the vaccine might also extend to individuals already exhibiting signs of cognitive decline or diagnosed with dementia. Using the same powerful natural experiment structure, they examined a broader spectrum of outcomes, ranging from mild cognitive changes to late-stage dementia.

Many cases of dementia are known to be preceded by a period of mild cognitive impairment (MCI), characterized by measurable deficits in memory and other cognitive skills that, while noticeable, do not yet severely interfere with independent living. The team observed that individuals who had received the shingles vaccine were significantly less likely to receive a diagnosis of mild cognitive impairment during a nine-year follow-up period than those who remained unvaccinated.

The results for individuals already living with dementia at the start of the Welsh vaccination program were particularly compelling. In this cohort, individuals with a pre-existing dementia diagnosis who received the shingles shot were significantly less likely to die from dementia in the subsequent nine years (as indicated on their death certificates) compared to those who did not receive the vaccine. This powerful finding suggests that the disease’s progression may have been considerably slowed in the vaccinated group. In total, nearly half of the 7,049 Welsh seniors who had dementia when the program began ultimately died from dementia during the follow-up period. Among those with dementia who received the vaccine, however, only about 30% died from dementia.

"The most exciting part is that this really suggests the shingles vaccine doesn’t have only preventive, delaying benefits for dementia, but also therapeutic potential for those who already have dementia," Geldsetzer commented, highlighting the profound implications of this discovery.

Another notable pattern emerged from the data when outcomes were analyzed by sex. The protective effect of the shingles vaccine against dementia appeared to be considerably stronger in women than in men. Dr. Geldsetzer suggested that this disparity might be attributable to underlying biological differences in immune responses between sexes or variations in the mechanisms of dementia development in men versus women. For instance, women generally tend to mount stronger antibody responses following vaccination, and shingles itself occurs more frequently in women than in men. These observations raise new and important questions for future research into sex-specific immunological and neurological pathways.

Unanswered Questions and the Path Forward: Towards an RCT

Despite the compelling evidence, the precise mechanisms by which the shingles vaccine might confer protection against dementia remain unclear. Scientists are still investigating whether the vaccine works by broadly stimulating the immune system, by specifically reducing the frequency or intensity of varicella-zoster virus reactivations (even asymptomatic ones), or through an entirely different pathway, such as modulating systemic inflammation.

Furthermore, the study utilized the live-attenuated shingles vaccine (Zostavax). It remains unknown whether the newer, more effective recombinant zoster vaccine (RZV, Shingrix), which uses only specific viral proteins and is now the preferred vaccine in many countries due to its superior efficacy in preventing shingles, would exert a similar or even stronger protective effect on dementia risk. This is a critical area for future investigation.

Dr. Geldsetzer hopes these groundbreaking findings will catalyze increased investment in this promising line of research. "At least investing a subset of our resources into investigating these pathways could lead to breakthroughs in terms of treatment and prevention," he urged.

His team has not confined their investigations to Wales alone. Over the past two years, they have cross-referenced health records from other countries, including England, Australia, New Zealand, and Canada, where similar shingles vaccine rollout strategies were implemented. The results from these diverse datasets have consistently echoed the protective signal observed in Wales. "We just keep seeing this strong protective signal for dementia in dataset after dataset," he confirmed, lending further credence to the initial findings.

The ultimate next step, according to Dr. Geldsetzer, is the execution of a large-scale randomized controlled trial (RCT). An RCT would provide the most rigorous and definitive evidence on whether the vaccine truly causes the observed reduction in dementia risk. In such a study, participants would be randomly assigned to receive either the live-attenuated shingles vaccine or a placebo injection, allowing for a direct and unbiased comparison. "It would be a very simple, pragmatic trial because we have a one-off intervention that we know is safe," he explained.

Dr. Geldsetzer is actively seeking philanthropic support to fund this crucial next phase of research. He noted that the live-attenuated vaccine, while the subject of his strong observational evidence, is now off-patent, which can complicate traditional pharmaceutical funding avenues for clinical trials. He also pointed out that such a trial might yield meaningful results relatively quickly. In the original Welsh data, when researchers charted the dementia rates for eligible versus ineligible individuals, the two curves began to diverge noticeably after approximately one and a half years, suggesting that a protective effect could manifest within a reasonable timeframe.

This research marks a significant step forward in understanding potential new pathways for dementia prevention and treatment, offering a glimmer of hope in the ongoing fight against a devastating global disease.

A researcher from the Vienna University of Economics and Business also contributed to the work.

The study received funding from The Phil & Penny Knight Initiative for Brain Resilience, the Stanford Center for Digital Health, the National Institute on Aging (grant R01AG084535), the National Institute of Allergy and Infectious Diseases (grant DP2AI171011) and the Biohub, San Francisco.